|
|
|
|
|
Zanaga,L.P.; Miotto,N.; Mendes,L.C.; Stucchi,R.S.B.; Vigani,A.G.. |
Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contraindications and... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Genotype 3; Sofosbuvir; Daclatasvir; Ribavirin. |
Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001100302 |
| |
|
|
Miotto,N.; Mendes,L.C.; Zanaga,L.P.; Goncales,E.S.L.; Lazarini,M.S.K.; Pedro,M.N.; Goncales Jr.,F.L.; Stucchi,R.S.B.; Vigani,A.G.. |
The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Protease inhibitor; Anemia; Adverse events; Treatment interruption. |
Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000700702 |
| |
|
|
|